Wells Fargo & Company Morpho Sys Ag Transaction History

Wells Fargo & Company

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$17.36 - $19.34 $29,303 - $32,645	-1,688 Reduced 80.84%	400 $7,000
Q1 2024 May 10, 2024	SELL	$8.6 - $18.18 $5,684 - $12,016	-661 Reduced 24.05%	2,088 $37,000
Q4 2023 Feb 09, 2024	SELL	$4.55 - $9.9 $234,320 - $509,840	-51,499 Reduced 94.93%	2,749 $27,000
Q3 2023 Nov 13, 2023	BUY	$6.72 - $8.6 $39,755 - $50,877	5,916 Added 12.24%	54,248 $364,000
Q2 2023 Aug 15, 2023	BUY	$3.95 - $7.74 $190,911 - $374,089	48,332 New	48,332 $361,000
Q4 2022 Feb 13, 2023	SELL	$3.21 - $5.74 $1,412 - $2,525	-440 Reduced 77.74%	126 $0
Q3 2022 Nov 14, 2022	SELL	$4.14 - $22.13 $1,159 - $6,196	-280 Reduced 33.1%	566 $3,000
Q2 2022 Aug 12, 2022	BUY	$4.51 - $7.39 $1,262 - $2,069	280 Added 49.47%	846 $4,000
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $14,463 - $23,974	-2,464 Reduced 81.32%	566 $4,000
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $8,217 - $11,267	905 Added 42.59%	3,030 $28,000
Q3 2021 Nov 15, 2021	SELL	$11.76 - $19.51 $110,144 - $182,730	-9,366 Reduced 81.51%	2,125 $25,000
Q2 2021 Aug 16, 2021	BUY	$18.95 - $23.95 $190,978 - $241,368	10,078 Added 713.23%	11,491 $221,000
Q1 2021 May 13, 2021	SELL	$21.56 - $30.66 $14,897 - $21,186	-691 Reduced 32.84%	1,413 $31,000
Q4 2020 Feb 09, 2021	BUY	$24.81 - $30.33 $124 - $151	5 Added 0.24%	2,104 $60,000
Q3 2020 Nov 05, 2020	BUY	$30.28 - $35.72 $968 - $1,143	32 Added 1.55%	2,099 $66,000
Q2 2020 Aug 13, 2020	BUY	$24.08 - $33.35 $13,581 - $18,809	564 Added 37.52%	2,067 $65,000
Q1 2020 May 14, 2020	BUY	$18.86 - $37.36 $28,346 - $56,152	1,503 New	1,503 $37,000

1.66M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.